US FDA Still Fighting Problems With Pre-ANDA Meeting Requests

More meeting requests are being denied because the sponsor's pre-meeting package was incomplete, the agency said.

Helping Hand_169455167_1200.jpg — The FDA granted more pre-ANDA meetings for complex generics through the first nine months of FY 2019 than in all of FY 2018. • Source: Shutterstock

Complex generic product sponsors seem to have a better handle on the purpose of the US Food and Drug Administration's pre-ANDA meeting program but still are struggling with the requirements.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

EU HTA Regulation: Don’t Forget About Vaccines, Industry Warns

18 Apr 2025

• By Eliza Slawther

Europe’s vaccines industry wants to make sure immunizations “are not forgotten” by policymakers who are overseeing the EU Health Technology Assessment Regulation. It has highlighted several nuances of vaccines that should be addressed over the coming years.

EU Pharmacopoeia Adopts ‘Groundbreaking’ Cell Therapy Chapter, Seeks Feedback On Alternative Microbiological Tests

18 Apr 2025

• By Neena Brizmohun

A new chapter that will be published in the European Pharmacopoeia soon is expected to provide a comprehensive framework for the production and quality control of cell-based preparations. Meanwhile, an existing chapter has been revised to facilitate the implementation of rapid microbiological testing methods.